Bluejay Diagnostics (BJDX) AI Stock Analysis

• Market Cap: $2.35M
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: N/A
• EPS Growth: 81.35%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -685.13
• Shares Outstanding: 1,494,182
• 10 Day Avg. Volume: 40,017
• 30 Day Avg. Volume: 1,315,069
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.36
• Enterprise Value/Market Cap: -0.20
• Enterprise Value/Revenue: -0.14
• Enterprise Value/Gross Profit: -8.80
• Enterprise Value/Ebitda: 0.02
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 29 Underperform
• Price Target: ―

Bluejay Diagnostics' stock is heavily impacted by its poor financial performance, with no revenue and continuous losses. The technical indicators suggest a bearish trend, and valuation is challenging due to the negative P/E ratio. Improvements in equity are noted but overshadowed by the lack of profitability and revenue generation.

Bluejay Diagnostics Business Overview & Revenue Model

Company Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Bluejay Diagnostics generates revenue through the sale of its Symphony System and associated consumables. The Symphony System is marketed to hospitals, clinics, and other healthcare facilities that require rapid diagnostic testing capabilities. The company may also engage in partnerships or collaborations with other healthcare entities to expand the reach and application of its technology. Additionally, Bluejay may generate revenue from licensing its technology or entering into strategic alliances with larger diagnostic or healthcare companies. These key revenue streams, along with potential government or institutional contracts, contribute to the company's overall earnings.

Bluejay Diagnostics Financial Statement Overview

Summary

Bluejay Diagnostics faces considerable financial challenges, with no revenue generation and persistent net losses over several years. While there have been improvements in equity, the overall financial health remains weak, reflecting high risk and dependency on external financing. Stabilizing revenue and improving cash flow management are critical for future growth and sustainability.

Income Statement

The company has consistently reported zero revenue with negative net income over multiple years. The lack of revenue growth and persistent net losses indicate a significant challenge in achieving profitability. This situation reflects a high risk in the income statement.

Balance Sheet

The company shows a substantial improvement in stockholders' equity from negative to positive, which is a positive sign. However, the debt-to-equity ratio is unfavorable due to high total liabilities relative to equity, and the equity ratio has been fluctuating. These mixed results indicate some improvements but also ongoing financial instability.

Cash Flow

Operating and free cash flows have been consistently negative, indicating operational difficulties. Although financing activities have provided cash inflows, reliance on external financing could be unsustainable. The cash flow situation suggests significant cash management challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	249.04K	0.00	0.00
Gross Profit	0.00	-780.96K	48.91K	-145.72K	-157.04K
EBITDA	-6.70M	-9.17M	-8.99M	-3.08M	-1.04M
Net Income	-7.72M	-9.95M	-9.23M	-3.73M	-1.13M
Balance Sheet
Total Assets	6.66M	4.87M	13.52M	21.02M	1.52M
Cash, Cash Equivalents and Short-Term Investments	4.30M	2.21M	10.11M	19.05M	912.36K
Total Debt	222.25K	352.98K	492.62K	0.00	1.06M
Total Liabilities	927.92K	1.97M	1.98M	637.16K	5.72M
Stockholders Equity	5.73M	2.89M	11.54M	20.38M	-4.21M
Cash Flow
Free Cash Flow	-8.13M	-9.02M	-8.94M	-4.39M	-508.71K
Operating Cash Flow	-7.82M	-8.31M	-7.74M	-4.37M	-508.71K
Investing Cash Flow	-306.78K	-704.17K	-1.20M	-23.95K	0.00
Financing Cash Flow	10.22M	1.11M	8.07K	22.53M	1.33M

Bluejay Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 1.57 is below the 20-day moving average (MA) of 1.62, below the 50-day MA of 1.71, and below the 200-day MA of 3.39, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 42.11 is Neutral, neither overbought nor oversold. The STOCH value of 21.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.

Bluejay Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.36B	-0.07	-63.77%	2.81%	16.35%	0.03%
TIVC	43 Neutral	$3.90M	―	-218.77%	―	-33.67%	91.72%
VTAK	41 Neutral	$2.92M	―	-136.26%	―	9.57%	10.03%
HSDT	39 Underperform	$6.02M	―	-800.00%	―	-35.03%	57.39%
BJDX	29 Underperform	$2.35M	―	-200.56%	―	―	81.35%
BBLG	―	$4.59M	―	-129.48%	―	―	―
IVF	39 Underperform	$5.46M	―	-679.99%	―	55.17%	40.47%